Home > > > > > Report Detail

Primary Progressive Multiple Sclerosis (PPMS) - Epidemiology Forecast to 2028

Publisher Name :
Date: 15-Jan-2019
No. of pages: 50
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Primary Progressive Multiple Sclerosis (PPMS) - Epidemiology Forecast, 2028" report provides a comprehensive analysis of the Primary Progressive Multiple Sclerosis (PPMS) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered

- United States

- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

- Japan

Study Period: 2016-2028

Primary Progressive Multiple Sclerosis (PPMS) Epidemiology

The epidemiology section covers the historical, current as well as forecasted epidemiology for Primary Progressive Multiple Sclerosis (PPMS) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders' views are also taken into account to provide a deep understanding of the Primary Progressive Multiple Sclerosis (PPMS) outlook. It also includes the explanation of changing trends of epidemiology outlining the Primary Progressive Multiple Sclerosis (PPMS) scenario.

Primary Progressive Multiple Sclerosis (PPMS) Epidemiology Segmentation

The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Primary Progressive Multiple Sclerosis (PPMS) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope

- The report covers detailed overview of Primary Progressive Multiple Sclerosis (PPMS) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

- It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan

- The Primary Progressive Multiple Sclerosis (PPMS) Report assesses the disease risk and burden and highlights the unmet needs

- It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths

- 10 Year Forecast

- 7MM Coverage

- Total Cases in Primary Progressive Multiple Sclerosis (PPMS)

Key assessments

- Patient Segmentation in Primary Progressive Multiple Sclerosis (PPMS)

- Primary Progressive Multiple Sclerosis (PPMS) Risk & Burden

- Factors driving growth in a specific Primary Progressive Multiple Sclerosis (PPMS) patient population

Primary Progressive Multiple Sclerosis (PPMS) - Epidemiology Forecast to 2028

Table of Contents

1. Report Introduction
2. Primary Progressive Multiple Sclerosis (PPMS) Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Primary Progressive Multiple Sclerosis (PPMS) in 2016
2.2. Patient Share Distribution of Primary Progressive Multiple Sclerosis (PPMS) in 2028
3. Disease Background and Overview: Primary Progressive Multiple Sclerosis (PPMS)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Primary Progressive Multiple Sclerosis (PPMS) in 7MM
4.3. Total Prevalent/ Incident Patient Population of Primary Progressive Multiple Sclerosis (PPMS) in 7MM - By Countries
5. Epidemiology of Primary Progressive Multiple Sclerosis (PPMS) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.1.3. Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.1.4. Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.1.5. Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.4.3. Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.4.4. Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.4.5. Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.5.3. Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.5.4. Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.5.5. Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.6.3. Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.6.4. Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.6.5. Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.7.3. Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.7.4. Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.7.5. Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.8.3. Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.8.4. Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.8.5. Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.9.3. Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.9.4. Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.9.5. Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS)
6. Unmet Needs of the Primary Progressive Multiple Sclerosis (PPMS)
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

List of Tables

Table 1: Total Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in United States (2016-2028)*
Table 6: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in France (2016-2028) *
Table 13: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in France (2016-2028) *
Table 14: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in UK (2016-2028) *
Table 26: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Japan (2016-2028)

List of Figures

Figure 1: Total Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in France (2016-2028) *
Figure 14: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Japan (2016-2028)

  • Global Fingolimod Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 74
    The global Fingolimod market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Fingolimod is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Fingolimod is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
  • Global Multiple Sclerosis Drugs Market Research Report 2024
    Published: 04-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The Multiple Sclerosis Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Multiple Sclerosis Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provi......
  • Global Multiple Sclerosis Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 21-Dec-2023        Price: US 3380 Onwards        Pages: 118
    Market Overview of Global Multiple Sclerosis market: According to our latest research, the global Multiple Sclerosis market looks promising in the next 5 years. As of 2022, the global Multiple Sclerosis market was estimated at USD 13809.22 million, and it's anticipated to reach USD 21672.55 million in 2028, with a CAGR of 7.8% during the forecast years. Multiple sclerosis (MS) is a chronic inflammatory neuropathy characterized by demyelination, axonal transection, and neurode......
  • Fingolimod - Global Market Insights and Sales Trends 2024
    Published: 21-Dec-2023        Price: US 3350 Onwards        Pages: 77
    The global Fingolimod market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Fingolimod in various end use industries. The expanding demands from the Medical Field, Science Research Field and Other Fields,, are propelling Fingolimod market. Oral, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Inj......
  • Global Fingolimod Market Research Report 2023, Forecast to 2028
    Published: 19-Dec-2023        Price: US 2680 Onwards        Pages: 133
    Fingolimod, sold under the brand name Gilenya, is an immunomodulating medication, mostly used for treating multiple sclerosis (MS). Fingolimod is a sphingosine-1-phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from contributing to an autoimmune reaction. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) dat......
  • Global Fingolimod Professional Survey Report 2023, Forecast to 2028
    Published: 19-Dec-2023        Price: US 3280 Onwards        Pages: 101
    Fingolimod, sold under the brand name Gilenya, is an immunomodulating medication, mostly used for treating multiple sclerosis (MS). Fingolimod is a sphingosine-1-phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from contributing to an autoimmune reaction. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) dat......
  • Multiple Sclerosis Drugs - Global Market Insights and Sales Trends 2024
    Published: 19-Dec-2023        Price: US 3350 Onwards        Pages: 96
    This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking By Company; 3) comprehensive presentation of the global market for Multiple Sclerosis Drugs, with both qu......
  • Global Multiple Sclerosis Drugs Market Research Report 2023
    Published: 25-Oct-2023        Price: US 2900 Onwards        Pages: 87
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Multiple Sclerosis Drugs market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Biogen - Sanofi - Novartis - Teva - Merck KGaA - Bayer - ACORDA - Mallinckrodt Segment by Type - Injectable......
  • Global Multiple Sclerosis Drugs Market Insights: Impact of COVID-19 and Future Expectations to 2028
    Published: 13-Jun-2023        Price: US 3260 Onwards        Pages: 122
    Multiple sclerosis (MS) is the most common disabling neurological disease in young people worldwide. The Multiple Sclerosis Drugs market revenue was 15099.44 Million USD in 2022, and will reach 23584.78 Million USD in 2028, with a CAGR of 7.72% during 2022-2028. This report elaborates the market size, market characteristics, and market growth of the Multiple Sclerosis Drugs industry, and breaks down according to the type, application, and consumption area of Multiple Sclero......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs